{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:40:23Z","timestamp":1792172423250,"version":"4.4.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jneuroim.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T19:47:16Z","timestamp":1468352836000},"page":"79-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-2416","authenticated-orcid":false,"given":"Christine","family":"Lebrun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Bourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Bresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alessandra","family":"Rosenthal-Allieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Desnuelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ticchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jneuroim.2016.07.009_bb0005","first-page":"659","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"JNNP"},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nmd.2015.03.014","article-title":"Selective response to rituximab in a young child with MuSK-associated myasthenia gravis","volume":"25","author":"Govindarajan","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"9","key":"10.1016\/j.jneuroim.2016.07.009_bb0025","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2016.07.009_bb0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"6","author":"Lebrun","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis \u2013 experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.jneuroim.2016.07.009_bb0040","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Lorio","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0045","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI58743","article-title":"Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity","volume":"122","author":"Maurer","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.11.006","article-title":"Rituximab induces clonal expansion of IgG memory B cells in patients with inflammatory central demyelination","volume":"290","author":"Maurer","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2016.07.009_bb0055","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","article-title":"Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment","volume":"48","author":"Yi","year":"2013","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572816301631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572816301631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:28:03Z","timestamp":1759048083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572816301631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":11,"alternative-id":["S0165572816301631"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2016.07.009","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}